Contents

Welcome Message ........................................................................................................ iii
EULAR 2014 Abstracts Reviewers .................................................................................... iv

Speakers Abstracts

Speaker Presentations

Wednesday, 11 June 2014

SP0001  Welcome session for all health care professional attendees ............................ 2
SP0002–SP0004  Giant cell arteritis: new perspectives ................................................. 2
SP0005–SP0007  Markers of osteoarthritis: what has it brought and what will it bring us 3
SP0008  HOT session 1: Comorbidity in rheumatic diseases / Systemic lupus erythematosus 3
SP0009–SP0010  Chronic periaortitis and IgG4 related diseases .............................. 4
SP0111  Adaptive immunity ................................................................. 4
SP0012–SP0013  Gout. Why crystals inflame, where they are located and how they may form 5
SP0014–SP0015  Health professionals and ultrasound - how to implement imaging into clinical practice 5
SP0016  Basic epidemiology explained ................................................................. 5
SP0017  EULAR projects in investigative rheumatology ............................................. 5
SP0018–SP0019  MRI basic I ................................................................. 6
SP0020–SP0021  Ultrasound basic I ................................................................. 6
SP0022–SP0025  Food as therapy - supporting healthy choices ............................ 6
SP0026–SP0027  Biosimilars: a SWOT analysis ...................................................... 7
SP0028–SP0029  Managing neck and shoulder pain ................................................ 8
SP0030  HOT session 2: Sjögren’s syndrome / Myositis ........................................... 8
SP0031–SP0033  Biomarkers: the future or a waste of resources? ......................... 9
SP0034–SP0035  Raynaud’s phenomenon and rheumatic diseases: primary versus secondary 9
SP0036–SP0038  PMR - establishing therapeutic order at last .................................. 10
SP0039–SP0040  Circadian rhythms and chronomodulation of the immune/inflammatory response 11
SP0041–SP0042  Spondyloarthritis: revisiting gut, enthesis and HLA-B27 in the IL23 era 11
SP0043–SP0044  Promoting a healthy lifestyle among patients with arthritis - how are health professionals doing? 12
SP0045–SP0046  Basic immunology explained ...................................................... 13
SP0047–SP0048  Educational activities within EULAR ESCET (EULAR Standing Committee for Education and Training) ........................................................................ 13
SP0049–SP0050  Political campaigning ................................................................. 14

Thursday, 12 June 2014

SP0051–SP0053  Lipid mediators and inflammation .................................................. 14
SP0054  Stem cells and inflammation ...................................................................... 15
SP0055  WIN session 2: Pain and fibromyalgia / Physical therapy ................................ 15
SP0056  HOT session 3: Vasculitis / Raynaud’s phenomenon and systemic sclerosis 15
SP0057–SP0058  I-Patient - the role of smart decision making ................................ 16
SP0059  WIN session 3: Early arthritis / Myositis ..................................................... 16
SP0060–SP0061  Analgesics for rheumatic diseases: re-thinking old drugs ................ 16
SP0062–SP0064  Imaging biomarkers in arthritis. Are MRI/US useful tools? ............ 17
SP0065–SP0066  What is the target in RA ............................................................... 18
SP0067–SP0069  Development and implementation of outcome measures ............... 18
SP0070–SP0071  Anti-TNF treatment. How do we stand regarding tuberculosis and cancer 19
SP0072  Autoinflammatory diseases ....................................................................... 20
SP0073–SP0074  Joint development - a magic toolbox for the rheumatologist .......... 20
SP0075–SP0076  Proteasome ................................................................................. 21
SP0077–SP0080  Targets and mechanisms of treatment in chronic pain ................ 21
### Friday, 13 June 2014

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP0120</td>
<td>EULAR-EFIS session: Innate lymphoid cells ILC’s in health and disease</td>
<td>32</td>
</tr>
<tr>
<td>SP0124</td>
<td>Joint homeostasis in OA</td>
<td>32</td>
</tr>
<tr>
<td>SP0125–SP0126</td>
<td>WIN session 5: Clinical implications of imaging advances / Osteoporosis and bone diseases</td>
<td>34</td>
</tr>
<tr>
<td>SP0126–SP0128</td>
<td>HOT session 5: Fibromyalgia / Spondyloarthitis/ankylosing spondylitis</td>
<td>34</td>
</tr>
<tr>
<td>SP0127–SP0128</td>
<td>Therapeutic drug monitoring</td>
<td>35</td>
</tr>
<tr>
<td>SP0129–SP0130</td>
<td>HOT session 6: Localised rheumatic syndromes / Osteoarthritis</td>
<td>35</td>
</tr>
<tr>
<td>SP0131–SP0132</td>
<td>Glucocorticoids as confounders</td>
<td>36</td>
</tr>
<tr>
<td>SP0133–SP0134</td>
<td>Future hot topics</td>
<td>36</td>
</tr>
<tr>
<td>SP0135–SP0136</td>
<td>Preclinical models of rheumatic disease. What do they teach us?</td>
<td>37</td>
</tr>
<tr>
<td>SP0137</td>
<td>Long-non coding RNAs/epigenetics</td>
<td>37</td>
</tr>
<tr>
<td>SP0138–SP0141</td>
<td>Is it a flare? Focus on patient self-reported disease activity measures in RA</td>
<td>37</td>
</tr>
<tr>
<td>SP0142–SP0144</td>
<td>EULAR projects in musculoskeletal imaging</td>
<td>38</td>
</tr>
<tr>
<td>SP0145</td>
<td>MRI basic II</td>
<td>39</td>
</tr>
<tr>
<td>SP0146</td>
<td>Improving your graphs and tables for publication and presentation I</td>
<td>39</td>
</tr>
<tr>
<td>SP0147–SP0150</td>
<td>Healthy ageing I - growing up with an RMD</td>
<td>39</td>
</tr>
<tr>
<td>SP0151</td>
<td>WIN session 7: Infections and rheumatic diseases / Comorbidity in rheumatic diseases</td>
<td>40</td>
</tr>
<tr>
<td>SP0152–SP0153</td>
<td>Clinical use of glucocorticoid</td>
<td>41</td>
</tr>
<tr>
<td>SP0154</td>
<td>Axial spondyloarthitis: new name of an old disease</td>
<td>41</td>
</tr>
<tr>
<td>SP0155</td>
<td>HOT session 7: Gout treatment and a touch on CPPD treatment / Imaging in diagnosis and management</td>
<td>41</td>
</tr>
<tr>
<td>SP0156–SP0158</td>
<td>Improving access to rheumatologist for patients with inflammatory arthritis</td>
<td>42</td>
</tr>
<tr>
<td>SP0159–SP0160</td>
<td>Innate regulation of inflammation</td>
<td>42</td>
</tr>
<tr>
<td>SP0161–SP0162</td>
<td>Novel auto-antibodies</td>
<td>43</td>
</tr>
<tr>
<td>SP0163–SP0164</td>
<td>Organ manifestations in scleroderma</td>
<td>43</td>
</tr>
<tr>
<td>SP0165–SP0167</td>
<td>Practical implementation of annual reviews in patients with inflammatory arthritis - sharing experiences</td>
<td>44</td>
</tr>
<tr>
<td>SP0168</td>
<td>How to get involved and how to influence the work of Eular health professionals</td>
<td>45</td>
</tr>
<tr>
<td>SP0169</td>
<td>MRI advanced I</td>
<td>45</td>
</tr>
<tr>
<td>SP0170–SP0173</td>
<td>Capillaroscopy II</td>
<td>45</td>
</tr>
<tr>
<td>SP0174–SP0177</td>
<td>Healthy ageing II - growing older with an RMD</td>
<td>47</td>
</tr>
</tbody>
</table>

### Saturday, 14 June 2014

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP0178</td>
<td>WIN session 8: Sjögren’s syndrome / Gout and crystal diseases</td>
<td>47</td>
</tr>
<tr>
<td>SP0179–SP0180</td>
<td>Early systemic sclerosis</td>
<td>48</td>
</tr>
<tr>
<td>SP0181–SP0183</td>
<td>Osteoimmunology, from bench to bedside. How to interpret new findings</td>
<td>48</td>
</tr>
<tr>
<td>SP0184–SP0185</td>
<td>HOT session 8: Juvenile idiopathic arthritis JIA and other paediatric diseases / Psoriatic arthritis</td>
<td>49</td>
</tr>
<tr>
<td>SP0186–SP0188</td>
<td>Optimal usage of longitudinal databases</td>
<td>49</td>
</tr>
</tbody>
</table>
Contents

OP0293–OP0294 From the general to the particular ......................................................... 172
OP0295–OP0296 Role of hypoxia in rheumatic disease ..................................................... 174
OP0297–OP0298 Sterile inflammation ...................................................................... 174
OP0299-HPR Patient education for people with inflammatory rheumatic disease ......................... 175
OP0300-PARE–OP0301-PARE Peer support in chronic diseases ......................................................... 175

Late Breaking Abstract
Thursday, 12 June 2014
LB0001 Abstract session: Novel non-TNF biologics treatment of RA ................................. 176

Poster Presentations
Thursday, 12 June 2014

Guided Poster Tours
T1: Clinical aspects and management of psoriatic arthritis
(SAT0408, SAT0413, SAT0384, SAT0411, SAT0403, SAT0385, SAT0387, SAT0400, SAT0386, SAT0381)
T2: Emerging concepts in genomics and genetics
(THU0460, THU0482, THU0454, THU0456, THU0468, THU0488, THU0480, THU0475, THU0491, THU0477)
T3: Infection-related rheumatic disease
(THU0282, THU0299, THU0290, THU0289, THU0296, THU0295, THU0283, THU0300, THU0281, THU0287)
T4: Scleroderma and myositis - clinical aspects
(FRI0481, FRI0484, FRI0480, FRI0479, FRI0482, FRI0497, FRI0485, FRI0505, FRI0478)
T5: PreS
(FRI0528, FRI0531, FRI0556, FRI0550, FRI0554, FRI0547, FRI0544, FRI0560, FRI0553)
T6: SLE, Sjögren’s an APS: etiology, pathogenesis and animal models
(THU0040, THU0047, THU0043, THU0054, THU0048, THU0055, THU0053, THU0051, THU0057, THU0042)
T8: Osteoarthritis - treatment and markers
(SAT0450, SAT0427, SAT0415, SAT0447, SAT0448, SAT0419, SAT0417, SAT0418, SAT0425)
T9: Managing RA and beyond
(FRI0093, FRI0090, FRI0055, FRI0054, FRI0095, FRI0099, FRI0075, FRI0073)
T10: Spondyloarthritis - clinical aspects
(FRI0119, FRI0155, FRI0154, FRI0139, FRI0115, FRI0147, FRI0114, FRI0111, FRI0112, FRI0150)
T11: RA: prediction of outcome
(SAT0042, SAT0043, SAT0050, SAT0063, SAT0040, SAT0035, SAT0047, SAT0036, SAT0054, SAT0038)

Posters
THU0001–THU0037 SLE, Sjögren’s and APS - clinical aspects (other than treatment) ......................... 177
THU0038–THU0059 SLE, Sjögren’s and APS - etiology, pathogenesis and animal models ..................... 189
THU0060–THU0108 Spondyloarthritis - clinical aspects (other than treatment) ................................. 197
THU0109–THU0150 Rheumatoid arthritis - non biologic treatment and small molecules ............................ 215
THU0151–THU0191 Rheumatoid arthritis - anti-TNF therapy .......................................................... 231
THU0192–THU0224 Osteoarthritis ......................................................... 248
THU0225–THU0279 Rheumatoid arthritis - prognosis, predictors and outcome ................................. 259
THU0280–THU0304 Infection-related rheumatic diseases ............................................................ 280
THU0305–THU0330 Fibromyalgia and pain in rheumatic diseases ..................................................... 288
THU0331–THU0359 Back pain, mechanical musculoskeletal problems, local soft tissue disorders ............ 296
THU0360–THU0409 Other orphan diseases .................................................................................. 307
THU0410–THU0453 Epidemiology, health services and outcome research ........................................ 323
THU0454–THU0494 Genomics, genetics and epigenetics of rheumatic diseases ................................. 340
THU0495–THU0510 Adaptive immunity (T cells and B cells) in rheumatic diseases ......................... 354
THU0511–THU0519 Innate immunity in rheumatic diseases ............................................................ 360
THU0520–THU0555 Cytokines and inflammatory mediators ............................................................ 363
THU0556–THU0571 Rehabilitation ................................................................................................. 375
Friday, 13 June 2014

Guided Poster Tours

F1: RA - non biologic and small molecules
   (THU0141, THU0140, THU0121, THU0115, THU0150, THU0134, THU0132, THU0114, THU0122)
F2: Epidemiology, health services research
   (THU0448, THU0453, THU0451, THU0412, THU0449, THU0424, THU0423, THU0433, THU0450)
F4: RA - Prognosis of outcome
   (SAT0044, SAT0053, SAT0041, SAT0052, SAT0059, SAT0056, SAT0055, SAT0051, SAT0073, SAT0049, SAT0058)
F6: Innate and adaptive immunity in rheumatic diseases
   (THU0514, THU0511, THU0516, THU0515, THU0519, THU0495, THU0503, THU0500, THU0507, THU0498)
F7: Crystal arthritis
   (SAT0503, SAT0510, SAT0516, SAT0502, SAT0545, SAT0505)
F8: Orphan diseases
   (THU0391, THU0382, THU0365, THU0362, THU0396, THU0395, THU0392, THU0377, THU0373)
F9: A walk in the treatment forest of SpA
   (SAT0364, SAT0373, SAT0344, SAT0351, SAT0357, SAT0376, SAT0358, SAT0332, SAT0331, SAT0371)
F10: The biology of rheumatoid arthritis
    (FRI0363, FRI0350, FRI0365, FRI0357, FRI0356, FRI0346, FRI0354)
F11: SLE, Sjögren’s and APS - clinical aspects (other than treatment)
    (THU0013, THU0023, THU0011, THU0008, THU0012, THU0014, THU0005, THU0001, THU0002)

Posters

<table>
<thead>
<tr>
<th>Code</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI0001–FRI0047</td>
<td>Rheumatoid arthritis - prognosis, predictors and outcome ................................ 381</td>
</tr>
<tr>
<td>FRI0048–FRI0108</td>
<td>Rheumatoid arthritis - comorbidity and clinical aspects ................................ 398</td>
</tr>
<tr>
<td>FRI0109–FRI0158</td>
<td>Spondyloarthritis - clinical aspects (other than treatment) .................. 421</td>
</tr>
<tr>
<td>FRI0159–FRI0169</td>
<td>Spondyloarthritis - etiology, pathogenesis and animal models .................. 439</td>
</tr>
<tr>
<td>FRI0170–FRI0224</td>
<td>Epidemiology, health services and outcome research .................................. 443</td>
</tr>
<tr>
<td>FRI0225–FRI0250</td>
<td>Diagnostics and imaging procedures .......................................................... 464</td>
</tr>
<tr>
<td>FRI0251–FRI0292</td>
<td>Rheumatoid arthritis - anti-TNF therapy ................................................. 474</td>
</tr>
<tr>
<td>FRI0293–FRI0336</td>
<td>Rheumatoid arthritis - other biologic treatment ....................................... 490</td>
</tr>
<tr>
<td>FRI0337–FRI0370</td>
<td>Rheumatoid arthritis - etiology, pathogenesis and animal models ................ 509</td>
</tr>
<tr>
<td>FRI0371–FRI0396</td>
<td>SLE, Sjögren’s and APS - treatment .......................................................... 521</td>
</tr>
<tr>
<td>FRI0397–FRI0440</td>
<td>SLE, Sjögren’s and APS - clinical aspects (other than treatment) ................. 531</td>
</tr>
<tr>
<td>FRI0442–FRI0477</td>
<td>Vasculitis ................................................................................................. 547</td>
</tr>
<tr>
<td>FRI0478–FRI0511</td>
<td>Scleroderma, myositis and related syndromes - clinical aspects and treatment ...... 560</td>
</tr>
<tr>
<td>FRI0512–FRI0525</td>
<td>Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models 573</td>
</tr>
<tr>
<td>FRI0526–FRI0527</td>
<td>Basic science in paediatric rheumatology ............................................... 577</td>
</tr>
<tr>
<td>FRI0528–FRI0560</td>
<td>Paediatric rheumatology ........................................................................ 578</td>
</tr>
</tbody>
</table>

Saturday, 14 June 2014

Guided Poster Tours

S1: Inside and outside the joint. What’s new in imaging?
   (FRI0249, FRI0246, FRI0226, FRI0227, FRI0225, FRI0247, FRI0231, FRI0239, FRI0248, FRI0250)
S3: Treatment options in SLE, what is new?
   (FRI0374, FRI0387, FRI0394, FRI0386, FRI0375, FRI0382, FRI0392, FRI0384, FRI0396)
S4: Vasculitis
   (FRI0455, FRI0461, FRI0474, FRI0463, FRI0473, FRI0460, FRI0476, FRI0477, FRI0456)
S5: Education in clinical rheumatology
   (SAT0584, SAT0575, SAT0581, SAT0577, SAT0587, SAT0588)
S6: Fibromyalgia and back pain
   (THU0329, THU0320, THU0328, SAT0579, THU0322, THU0330, THU0305, THU0314, THU0309, THU0341)
S7: RA anti-TNF
   (FRI0252, FRI0288, FRI0254, FRI0287, FRI0258, FRI0255, FRI0251, THU0159, THU0157)
S8: Rehabilitation
   (THU0571, THU0565, THU0562, THU0564, THU0560, THU0567, THU0570, THU0563, THU0568, THU0569)
S9: Osteoporosis
   (SAT0463, SAT0479, SAT0484, SAT0499, SAT0490, SAT0480, SAT0496, SAT0471, SAT0460, SAT0475)
Health Professionals in Rheumatology Abstracts

Oral Presentations

Wednesday, 11 June 2014

OP0005-HPR Adherence: the new challenge for rheumatology .................................................. 1180
OP0009-HPR Health professionals and ultrasound - how to implement imaging into clinical practice . 1180
OP0010-HPR Food as therapy - supporting healthy choices ..................................................... 1180
OP0019-HPR–OP0020-HPR Promoting a healthy lifestyle among patients with arthritis - how are health professionals doing? ................................................................................... 1181

Thursday, 12 June 2014

OP0081-HPR–OP0088-HPR Abstract session: Evaluating practice ..................................................... 1182
OP0132-HPR Targets and mechanisms of treatment in chronic pain ........................................ 1184
OP0137-HPR Patient’s perspectives in rheumatologic outcomes ............................................. 1185
OP0140-HPR eHealth literacy on rheumatic diseases - analysing the power of the internet .............. 1185

Friday, 13 June 2014

OP0203-HPR–OP0210-HPR Abstract session: Tracking the journey .................................................... 1185
OP0258-HPR Is it a flare? Focus on patient self-reported disease activity measures in RA ............... 1188
OP0269-HPR–OP0270-HPR Practical implementation of annual reviews in patients with inflammatory arthritis – sharing experiences ...................................................................... 1189

Saturday, 14 June 2014

OP0286-HPR–OP0287-HPR The scleroderma patient-centered intervention network (SPIN): meeting the challenges of research into a rare disease ............................................................ 1189
OP0299-HPR Patient education for people with inflammatory rheumatic disease ......................... 1190

Poster Presentations

Thursday, 12 June 2014

Posters
THU0572-HPR–THU0587-HPR Nursing .................................................................................. 1191
THU0588-HPR–THU0594-HPR Psychology/social sciences ............................................................... 1196

Friday, 13 June 2014

Guided Poster Tour
F3: HPR: Evaluating practice
(FRI0575-HPR, THU0584-HPR, THU0574-HPR, THU0592-HPR, THU0587-HPR, FRI0577-HPR, THU0580-HPR, FRI0578-HPR, THU0593-HPR)

Posters
FRI0561-HPR–FRI0591-HPR Physiotherapy ............................................................................ 1198
FRI0592-HPR–FRI0595-HPR Occupational therapy ..................................................................... 1209

Saturday, 14 June 2014

Guided Poster Tour
S2: HPR: Tracking the journey
(FRI0587-HPR, FRI0592-HPR, SAT0595-HPR, SAT0594-HPR, FRI0563-HPR, THU0591-HPR, THU0594-HPR, FRI0576-HPR, FRI0594-HPR)

Posters
SAT0589-HPR–SAT0595-HPR Miscellaneous forms of clinical care ...................................................... 1210

Abstracts Accepted for Publication

AB1137-HPR–AB1151-HPR Nursing .................................................................................. 1214
AB1152-HPR–AB1162-HPR Psychology/social sciences ............................................................... 1218
AB1163-HPR–AB1176-HPR Physiotherapy ............................................................................ 1222
AB1177-HPR–AB1179-HPR Occupational therapy ..................................................................... 1226
AB1180-HPR–AB1191-HPR Miscellaneous forms of clinical care ...................................................... 1227
People with Arthritis and Rheumatism in Europe Abstracts

Oral Presentations

Wednesday, 11 June 2014
OP0021-PARE–OP0022-PARE Political campaining ................................................................. 1234

Thursday, 12 June 2014
OP0121-PARE I-Patient - the role of smart decision making .................................................. 1234
OP0134-PARE Don’t let the economic crisis go to waste ......................................................... 1234

Friday, 13 June 2014
OP0243-PARE–OP0249-PARE Abstract session: PARE .......................................................... 1235
OP0259-PARE Healthy ageing I - growing up with an RMD .................................................. 1237
OP0273-PARE Healthy ageing II - growing older with an RMD ............................................... 1238

Saturday, 14 June 2014
OP0288-PARE Facilitating a normal life - easy travelling for people with RMDs ....................... 1238
OP0300-PARE–OP0301-PARE Peer support in chronic diseases ............................................ 1238

Poster Presentations

Guided Poster Tours

Thursday, 12 June 2014
PARE I (PARE0001 to PARE0011)

Friday, 13 June 2014
PARE II (PARE0012 to PARE0022)

Posters

Thursday, 12 June to Saturday, 14 June 2014
PARE0001 Building patient led organisations ................................................................. 1240
PARE0002–PARE0003 Best practice campaigning .......................................................... 1240
PARE0004–PARE0005 Patient information and education .................................................. 1241
PARE0006 Innovations in arthritis health care ................................................................. 1241
PARE0007 Patient information and education ................................................................. 1242
PARE0008–PARE0009 Best practice campaigning .......................................................... 1242
PARE0010–PARE0011 Patient information and education .................................................. 1243
PARE0012 Best practice campaigning ................................................................. 1243
PARE0013 Patient information and education ................................................................. 1244
PARE0014–PARE0015 Best practice campaigning .......................................................... 1244
PARE0016 Patient information and education ................................................................. 1244
PARE0017–PARE0018 Work and rehabilitation ................................................................. 1245
PARE0019 Best practice campaigning ................................................................. 1246
PARE0020 Patient information and education ................................................................. 1246
PARE0021 Psychosocial support ................................................................................. 1246
PARE0022 Best practice campaigning ................................................................. 1247

Author Index ........................................................................................................... 1249